DE602007005402D1 - Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht - Google Patents
Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschichtInfo
- Publication number
- DE602007005402D1 DE602007005402D1 DE602007005402T DE602007005402T DE602007005402D1 DE 602007005402 D1 DE602007005402 D1 DE 602007005402D1 DE 602007005402 T DE602007005402 T DE 602007005402T DE 602007005402 T DE602007005402 T DE 602007005402T DE 602007005402 D1 DE602007005402 D1 DE 602007005402D1
- Authority
- DE
- Germany
- Prior art keywords
- fast
- intermediate layer
- pharmaceutical formulations
- multilayer pharmaceutical
- resolved intermediate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86515706P | 2006-11-09 | 2006-11-09 | |
PCT/US2007/084177 WO2008060963A2 (en) | 2006-11-09 | 2007-11-08 | Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602007005402D1 true DE602007005402D1 (de) | 2010-04-29 |
Family
ID=39322569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602007005402T Active DE602007005402D1 (de) | 2006-11-09 | 2007-11-08 | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
Country Status (19)
Country | Link |
---|---|
US (6) | US8088786B2 (de) |
EP (1) | EP2089005B1 (de) |
JP (5) | JP2010509367A (de) |
KR (5) | KR101735466B1 (de) |
CN (1) | CN101588795A (de) |
AR (1) | AR063959A1 (de) |
AT (1) | ATE460925T1 (de) |
AU (1) | AU2007319471B9 (de) |
CA (1) | CA2668884C (de) |
CL (1) | CL2007003245A1 (de) |
DE (1) | DE602007005402D1 (de) |
DK (1) | DK2089005T3 (de) |
ES (1) | ES2344440T3 (de) |
HK (1) | HK1135026A1 (de) |
IL (2) | IL198577A (de) |
MX (1) | MX2009004874A (de) |
RU (1) | RU2452471C2 (de) |
TW (3) | TWI504419B (de) |
WO (1) | WO2008060963A2 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
ES2761812T3 (es) | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
TWI504419B (zh) * | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
KR20140088619A (ko) | 2006-11-09 | 2014-07-10 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
ES2555066T3 (es) | 2006-11-17 | 2015-12-28 | Supernus Pharmaceuticals, Inc. | Formulaciones de liberación sostenida de topiramato |
US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
EP2303025A4 (de) * | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Verfahren zur behandlung von eingeweidefettbeschwerden |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
WO2010045563A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010045416A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010045529A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113580A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010075275A1 (en) * | 2008-12-23 | 2010-07-01 | Usworldmeds Llc | Selective release of non-racemic mixtures of two enantiomers from tablets and capsules |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331420A1 (en) * | 2009-06-26 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2011008490A2 (en) * | 2009-06-29 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2011009115A2 (en) * | 2009-07-17 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2011041632A2 (en) * | 2009-10-01 | 2011-04-07 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
US20110280936A1 (en) * | 2010-05-17 | 2011-11-17 | Aptapharma, Inc. | Self Breaking Tablets |
US20120003312A1 (en) * | 2010-06-30 | 2012-01-05 | Aptapharma, Inc. | Multilayer Minitablets with Different Release Rates |
WO2012075453A1 (en) | 2010-12-03 | 2012-06-07 | Orexigen Therapeutics, Inc. | Methods for reducing binge or compulsive eating |
CN103313711A (zh) | 2010-12-03 | 2013-09-18 | 奥雷西根治疗公司 | 在纳曲酮疗法中增加药物生物可利用性 |
JP6112765B2 (ja) * | 2010-12-13 | 2017-04-12 | 第一三共ヘルスケア株式会社 | ロキソプロフェンナトリウム及びdl−メチルエフェドリン塩酸塩を含有する固形製剤 |
JP6110589B2 (ja) * | 2010-12-13 | 2017-04-05 | 第一三共ヘルスケア株式会社 | ロキソプロフェンナトリウムとクレマスチンフマル酸塩を含有する固形製剤 |
JP6126780B2 (ja) * | 2010-12-13 | 2017-05-10 | 第一三共ヘルスケア株式会社 | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 |
JP6106359B2 (ja) * | 2010-12-13 | 2017-03-29 | 第一三共ヘルスケア株式会社 | ロキソプロフェンナトリウムとビタミンb1を含有する固形製剤 |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
WO2013103919A2 (en) | 2012-01-06 | 2013-07-11 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
PT2661266T (pt) | 2011-01-07 | 2020-11-30 | Anji Pharma Us Llc | Terapias com base em ligandos do recetor quimiossensorial |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
ES2832773T3 (es) | 2012-01-06 | 2021-06-11 | Anji Pharma Us Llc | Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos |
US20130237504A1 (en) * | 2012-03-12 | 2013-09-12 | Mehdi El Glaoui | Pharmaceutical Forms and Methods for Designing the Same |
DK3730132T3 (da) | 2012-06-06 | 2022-08-08 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko |
JP6160263B2 (ja) * | 2012-06-07 | 2017-07-12 | 大正製薬株式会社 | ロキソプロフェン含有医薬組成物 |
EP2961390A1 (de) * | 2013-03-01 | 2016-01-06 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmazeutische formulierungen mit quetiapin und escitalopram |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
MX2017003561A (es) * | 2014-08-22 | 2017-08-28 | Medipath Inc | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. |
WO2016125108A1 (en) * | 2015-02-07 | 2016-08-11 | Intas Pharmaceuticals Ltd. | Bilayer pharmaceutical composition for the treatment of obesity |
EP3253379A4 (de) * | 2015-02-07 | 2018-10-10 | Intas Pharmaceuticals Limited | Pharmazeutische zusammensetzung zur behandlung von adipositas |
US10702548B2 (en) * | 2015-03-04 | 2020-07-07 | Joelle Michele Forbes | Compositions and methods for treating drug addiction |
WO2016141460A1 (en) * | 2015-03-11 | 2016-09-15 | The University Of British Columbia | Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) |
CN108430465A (zh) * | 2015-09-30 | 2018-08-21 | 韦尔斯利医药有限公司 | 用于缓解尿频的组合物、其制造方法和用途 |
US20200197315A1 (en) * | 2016-07-06 | 2020-06-25 | Durect Corporation | Oral dosage form with drug composition, barrier layer and drug layer |
CN111407734A (zh) * | 2019-01-05 | 2020-07-14 | 厦门赛诺邦格生物科技股份有限公司 | 一种阳痿早泄治疗药物的固体制剂 |
WO2021053542A1 (en) * | 2019-09-20 | 2021-03-25 | Dr. Reddy’S Laboratories Limited | Pharmaceutical compositions for obesity management |
KR102536511B1 (ko) * | 2020-06-25 | 2023-05-26 | (주) 넥스팜코리아 | 날트렉손 서방형 매트릭스 제제와 부프로피온 서방형 매트릭스 제제의 단층정 복합제제와 그 제조 방법 |
EP4243768A1 (de) * | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Mehrschichttablette mit sofortiger freisetzung |
AU2021390502A1 (en) | 2020-12-01 | 2023-06-22 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for reduction of suicide risk in depression patients |
US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
WO2024073334A1 (en) | 2022-09-26 | 2024-04-04 | Rose Research Center, Llc | Combination for use in a method of preventing weight gain |
Family Cites Families (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759838A (fr) | 1969-12-04 | 1971-06-03 | Wellcome Found | Cetones a activite biologique |
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
US3942641A (en) | 1972-05-05 | 1976-03-09 | Syntex Corporation | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens |
US4089855A (en) | 1976-04-23 | 1978-05-16 | Cornell Research Foundation, Inc. | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby |
GB1557082A (en) * | 1977-01-25 | 1979-12-05 | Fisons Ltd | Pharmaceutical mixture containing an antiinflammatory |
US4218433A (en) * | 1977-03-03 | 1980-08-19 | Nippon Kayaku Kabushiki Kaisha | Constant-rate eluting tablet and method of producing same |
US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
JPS58134019A (ja) * | 1982-02-05 | 1983-08-10 | Ono Pharmaceut Co Ltd | プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法 |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
US4895845A (en) | 1986-09-15 | 1990-01-23 | Seed John C | Method of assisting weight loss |
NL8800823A (nl) | 1987-04-10 | 1988-11-01 | Sandoz Ag | Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. |
ATE93721T1 (de) | 1987-05-04 | 1993-09-15 | Lilly Co Eli | Verwendung von fluoxetin zur behandlung des diabetes. |
US5000886A (en) | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
US5364841A (en) | 1988-01-11 | 1994-11-15 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
ES2062310T3 (es) | 1989-12-06 | 1994-12-16 | Akzo Nv | Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado. |
FR2657350B1 (fr) | 1990-01-19 | 1992-05-15 | Centre Nat Rech Scient | Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone. |
US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
US5213807A (en) * | 1990-05-03 | 1993-05-25 | Chemburkar Pramod B | Pharmaceutical composition containing ibuprofen and a prostaglandin |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
IT1256393B (it) * | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US6183778B1 (en) * | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
IT1265240B1 (it) * | 1993-11-30 | 1996-10-31 | Ekita Investments Nv | Compressa farmaceutica a rilascio controllato, di forma lenticolare |
EP0782445B1 (de) | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit |
US5714519A (en) | 1995-06-07 | 1998-02-03 | Ergo Science Incorporated | Method for regulating glucose metabolism |
ES2168610T3 (es) | 1996-03-12 | 2002-06-16 | Alza Corp | Composicion y forma galenica que contiene un antagonista opioide. |
US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
JPH11505547A (ja) * | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | ナルトレキソン及び関連化合物を用いる禁煙処置 |
IL121076A (en) | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
UA53655C2 (uk) | 1996-06-28 | 2003-02-17 | Орто-Макнейл Фармасьютікел, Інк. | Спосіб лікування ожиріння |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
JP2001527023A (ja) | 1997-08-11 | 2001-12-25 | アルザ・コーポレーション | 胃で保持するのに適合した長期放出性活性剤剤形 |
US6622036B1 (en) | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
DE69811378T2 (de) | 1997-10-03 | 2004-02-12 | Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion |
US6652882B1 (en) | 1997-10-06 | 2003-11-25 | Intellipharmaceutics Corp | Controlled release formulation containing bupropion |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
IL127497A (en) | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
DE69830512T2 (de) | 1997-12-26 | 2006-03-23 | Dainippon Pharmaceutical Co., Ltd. | Medikament für neurodegenerative Erkrankungen |
BR9907203A (pt) | 1998-01-21 | 2000-10-17 | Glaxo Group Ltd | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " |
JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な(−)−ビュープロピオンの薬学的使用 |
US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6153223A (en) | 1998-06-05 | 2000-11-28 | Watson Pharmaceuticals, Inc. | Stabilized pharmaceutical compositions |
US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US6033686A (en) | 1998-10-30 | 2000-03-07 | Pharma Pass Llc | Controlled release tablet of bupropion hydrochloride |
US6096341A (en) | 1998-10-30 | 2000-08-01 | Pharma Pass Llc | Delayed release tablet of bupropion hydrochloride |
EP1005863A1 (de) * | 1998-12-04 | 2000-06-07 | Synthelabo | Dosisformen mit gesteuerter Wirkstofffreigabe enthaltend ein kurzer wirkung Hypnotikum oder einem Salz davon |
US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
US6238697B1 (en) | 1998-12-21 | 2001-05-29 | Pharmalogix, Inc. | Methods and formulations for making bupropion hydrochloride tablets using direct compression |
US6635281B2 (en) | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
HUP0200469A3 (en) | 1999-02-24 | 2003-03-28 | Univ Cincinnati Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US20030035840A1 (en) | 2001-02-08 | 2003-02-20 | Boyong Li | Controlled release oral dosage form |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
US6387956B1 (en) | 1999-03-24 | 2002-05-14 | University Of Cincinnati | Methods of treating obsessive-compulsive spectrum disorders |
CN1329359C (zh) | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
CZ20013607A3 (cs) | 1999-04-06 | 2002-06-12 | Sepracor Inc. | Farmaceutický prostředek |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US7056890B2 (en) | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
EP2308481B1 (de) * | 1999-06-14 | 2015-05-06 | Vivus, Inc. | Kombinationstherapie zur Behandlung von Bluthochdruck bei Fettleibigkeit |
DE19927688A1 (de) * | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
US20040115134A1 (en) | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
CO5210862A1 (es) * | 1999-09-15 | 2002-10-30 | Alza Corp | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
US6410736B1 (en) | 1999-11-29 | 2002-06-25 | Pfizer Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
US20030144271A1 (en) | 2000-01-22 | 2003-07-31 | Albert Shulman | Methods for the treatment of substance abuse |
US20020090615A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
EP1263438B1 (de) | 2000-03-15 | 2006-05-17 | Wolfgang Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
US8030294B2 (en) | 2000-03-16 | 2011-10-04 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
US6437147B1 (en) | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
AU5066101A (en) | 2000-04-13 | 2001-10-30 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
AU2001250646A1 (en) | 2000-04-17 | 2001-10-30 | Yamanouchi Pharmaceutical Co..Ltd. | Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof |
US6761895B2 (en) | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
EP1326630B1 (de) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Verwendung von glp-2-peptiden |
JP2004518718A (ja) | 2000-10-30 | 2004-06-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗糖尿病薬および抗痙攣薬を含んで成る併用療法 |
US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US20030109546A1 (en) | 2001-04-26 | 2003-06-12 | Fenton Wayne S. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
EP1262196A3 (de) | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht |
US6960357B2 (en) | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
EP2163241A1 (de) * | 2001-06-01 | 2010-03-17 | Pozen, Inc. | Pharmazeutische Zusammensetzungen für die koordinierte Abgabe von NSAID |
US6462237B1 (en) | 2001-06-14 | 2002-10-08 | Usv Limited | Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20030044462A1 (en) | 2001-08-20 | 2003-03-06 | Kali Laboratories, Inc. | Sustained release tablets containing bupropion hydrochloride |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
ITFI20010230A1 (it) * | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
US20030133982A1 (en) | 2001-12-20 | 2003-07-17 | Heimlich John M. | Zero-order sustained release dosage forms and method of making same |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
KR101072885B1 (ko) | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
WO2004006959A1 (en) | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
ES2355723T3 (es) | 2002-09-11 | 2011-03-30 | Elan Pharma International Limited | Composiciones de agente activo en nanopartículas estabilizadas en gel. |
US20040105778A1 (en) | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
US20040092504A1 (en) | 2002-11-12 | 2004-05-13 | Anuthep Benja-Athon | Definitive medications for treating fibromyalgia |
US6893660B2 (en) | 2002-11-21 | 2005-05-17 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions without a stabilizer |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
US20040115265A1 (en) * | 2002-12-11 | 2004-06-17 | Loutfy Benkerrour | Multilayered tablet containing pravastatin and aspirin and method |
JP2006514986A (ja) * | 2002-12-13 | 2006-05-18 | シラグ・アクチエンゲゼルシヤフト | トラマドールおよびトピラメートを含んでなる制御放出調製物 |
ATE546134T1 (de) * | 2002-12-26 | 2012-03-15 | Pozen Inc | Mehrschichtige dosierformen enthaltend naproxen und triptane |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US20040158194A1 (en) | 2003-02-06 | 2004-08-12 | Wolff Andy And Beiski Ben Z. | Oral devices and methods for controlled drug release |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
WO2004087175A1 (en) | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
KR101167579B1 (ko) * | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
KR20060011873A (ko) | 2003-05-16 | 2006-02-03 | 화이자 프로덕츠 인코포레이티드 | 비정형 항정신약과 gaba 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물 |
US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
WO2005009417A1 (en) | 2003-07-21 | 2005-02-03 | Noven Pharmaceuticals, Inc. | Composition and method for controlling grug delivery from silicone adhesive blends |
US7759358B2 (en) | 2003-07-23 | 2010-07-20 | Crooks Peter A | Oral bioavailable prodrugs |
JP2007521231A (ja) | 2003-08-08 | 2007-08-02 | バイオヴェイル ラボラトリーズ インコーポレイテッド | 塩酸ブプロピオンの放出調節錠剤 |
CA2534924A1 (en) | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
US20050043705A1 (en) | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050043704A1 (en) | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
EP1656148A4 (de) * | 2003-08-21 | 2011-07-20 | Duchesnay Inc | Mikronährstoff-ergänzung |
US20050043773A1 (en) | 2003-08-21 | 2005-02-24 | Ivan Lieberburg | Methods of improving the safety of zonisamide therapy |
US20050112198A1 (en) | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US20050147664A1 (en) | 2003-11-13 | 2005-07-07 | Elan Pharma International Ltd. | Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery |
US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
US20050181049A1 (en) | 2003-11-19 | 2005-08-18 | Dong Liang C. | Composition and method for enhancing bioavailability |
WO2005065645A2 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
BRPI0506829A (pt) | 2004-01-13 | 2007-05-29 | Univ Duke | composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso |
JP2007522248A (ja) | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | てんかんおよび他のcns障害の処置のための、nmdaレセプターアンタゴニストと抗てんかん薬との組み合わせ |
US20050214371A1 (en) | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
WO2005107806A1 (en) | 2004-04-21 | 2005-11-17 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
RU2006139930A (ru) * | 2004-05-03 | 2008-06-10 | Дюк Юниверсити (Сша/Сша) (Us) | Составы для содействия снижению веса |
US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
RU2007103313A (ru) * | 2004-08-03 | 2008-09-10 | ОРЕКСИДЖЕН ТЕРАПЬЮТИКС, ИНК. (Канада/США) (US) | Комбинация бупропина и другого состава для эффективной потери веса |
EP1809104A4 (de) | 2004-09-23 | 2009-04-29 | Alexander Michalow | Verfahren zum regeln von neurotransmittersystemen durch gegenadaptationen |
WO2006055854A2 (en) | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
JP2006232675A (ja) * | 2005-02-22 | 2006-09-07 | Kowa Co | 複合型口腔内溶解用固形製剤 |
EP1859791B1 (de) * | 2005-03-10 | 2011-12-07 | Taisho Pharmaceutical Co., Ltd | Dragee |
AR053712A1 (es) | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
US20060246131A1 (en) | 2005-04-28 | 2006-11-02 | Cottlingham Elizabeth M | Use of metformin to counteract weight gain associated with psychotropic medications |
RU2007142346A (ru) | 2005-05-31 | 2009-07-20 | Ориксиджен Серапьютикс, Инкорпорэйтд (Сша/Сша) (Us) | Способы и составы для контроля психотических нарушений |
US20070117827A1 (en) | 2005-07-27 | 2007-05-24 | Gary Tollefson | Compositions for affecting weight loss |
ES2761812T3 (es) | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
WO2007064586A1 (en) | 2005-11-28 | 2007-06-07 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
JP2009517394A (ja) * | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | ゾニサミドの徐放性製剤 |
WO2007084290A2 (en) | 2006-01-12 | 2007-07-26 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain |
EP3626236A1 (de) * | 2006-06-05 | 2020-03-25 | Nalpropion Pharmaceuticals, Inc. | Formulierung aus naltrexon mit verzögerter freisetzung |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
WO2008011150A1 (en) | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
TWI504419B (zh) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
KR20140088619A (ko) | 2006-11-09 | 2014-07-10 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
US8071918B2 (en) | 2007-10-30 | 2011-12-06 | Prince Castle LLC. | Controller for a food holding oven |
EP2303025A4 (de) * | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Verfahren zur behandlung von eingeweidefettbeschwerden |
CN102724878A (zh) * | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
-
2007
- 2007-11-08 TW TW096142297A patent/TWI504419B/zh active
- 2007-11-08 US US11/937,421 patent/US8088786B2/en active Active
- 2007-11-08 KR KR1020147021316A patent/KR101735466B1/ko active IP Right Grant
- 2007-11-08 KR KR1020197010891A patent/KR20190042766A/ko not_active Application Discontinuation
- 2007-11-08 CN CNA2007800494404A patent/CN101588795A/zh active Pending
- 2007-11-08 AT AT07864161T patent/ATE460925T1/de active
- 2007-11-08 KR KR1020097011226A patent/KR101479324B1/ko active IP Right Grant
- 2007-11-08 JP JP2009536494A patent/JP2010509367A/ja active Pending
- 2007-11-08 WO PCT/US2007/084177 patent/WO2008060963A2/en active Application Filing
- 2007-11-08 KR KR1020157009741A patent/KR101654176B1/ko active IP Right Grant
- 2007-11-08 RU RU2009116835/15A patent/RU2452471C2/ru active
- 2007-11-08 KR KR1020167035323A patent/KR101971218B1/ko active IP Right Grant
- 2007-11-08 DE DE602007005402T patent/DE602007005402D1/de active Active
- 2007-11-08 AR ARP070104991A patent/AR063959A1/es not_active Application Discontinuation
- 2007-11-08 TW TW104113742A patent/TWI609702B/zh active
- 2007-11-08 DK DK07864161.0T patent/DK2089005T3/da active
- 2007-11-08 ES ES07864161T patent/ES2344440T3/es active Active
- 2007-11-08 EP EP07864161A patent/EP2089005B1/de active Active
- 2007-11-08 CA CA2668884A patent/CA2668884C/en active Active
- 2007-11-08 MX MX2009004874A patent/MX2009004874A/es active IP Right Grant
- 2007-11-08 AU AU2007319471A patent/AU2007319471B9/en active Active
- 2007-11-08 TW TW106126885A patent/TW201811315A/zh unknown
- 2007-11-09 CL CL200703245A patent/CL2007003245A1/es unknown
-
2009
- 2009-05-05 IL IL198577A patent/IL198577A/en active IP Right Grant
-
2010
- 2010-02-11 HK HK10101556.2A patent/HK1135026A1/xx unknown
-
2011
- 2011-12-19 US US13/330,395 patent/US8318788B2/en active Active
-
2012
- 2012-11-19 US US13/680,922 patent/US20130177602A1/en not_active Abandoned
-
2014
- 2014-02-20 JP JP2014030437A patent/JP5908008B2/ja active Active
- 2014-07-01 IL IL233471A patent/IL233471A0/en unknown
- 2014-11-14 US US14/541,525 patent/US20150164806A1/en not_active Abandoned
-
2015
- 2015-11-18 JP JP2015225519A patent/JP6240140B2/ja active Active
-
2016
- 2016-01-05 US US14/988,556 patent/US20160338965A1/en not_active Abandoned
-
2017
- 2017-01-04 JP JP2017000075A patent/JP6353089B2/ja active Active
-
2018
- 2018-05-28 JP JP2018101297A patent/JP6633130B2/ja active Active
-
2023
- 2023-05-04 US US18/143,254 patent/US20230301922A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602007005402D1 (de) | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht | |
NO2019027I1 (no) | kobicistat eller et farmasøytisk akseptabelt salt derav | |
DE602006018529D1 (de) | Mehrschichtige tablette mit dreifacher freisetzungskombination | |
DE602007010797D1 (de) | Pharmazeutische zusammensetzungen mit rosuvastatin-calcium | |
ATE493119T1 (de) | Pharmazeutische zusammensetzung | |
ATE532788T1 (de) | Pharmazeutische verbindungen | |
EP2170603A4 (de) | Mehrlagiger sperrfilm | |
IL195223A0 (en) | Pharmaceutical form with multilayer separating layer | |
ATE452839T1 (de) | Kapsel mit reduziertem nachtropfen | |
DK2399580T3 (da) | Farmaceutiske doseringsformer | |
DK2692341T3 (da) | Misbrugs-resistent lægemiddelformulering | |
BRPI0922253A2 (pt) | filme de superfície para compósitos com camada de barreira. | |
ATE517619T1 (de) | Stabilisierte pharmazeutische zusammensetzung mit fesoterodin | |
DK2144966T3 (da) | Flerlagsstruktur | |
DE602007001173D1 (de) | Nanolaminat-Wärmesperrbeschichtungen | |
DE502007002499D1 (de) | Bauteil mit einer panzerung | |
BRPI0812805A2 (pt) | Formas de dosagem marcadas a laser | |
BRPI0817833A2 (pt) | Composição farmacêutica antimalárica | |
DE502007006594D1 (de) | Ein-oder mehrschichtige, stabilisierte Polyesterfolie | |
DE502007001073D1 (de) | Gurtaufroller mit kupplungsblockade | |
ITPD20060022A1 (it) | Film laminato multistrato | |
ATE530164T1 (de) | Wässrige pharmazeutische zubereitung | |
DE602007008384D1 (de) | Formbeschichtungen mit ungleichmässiger dosierung | |
DK2187889T3 (da) | Anvendelse af purinderivater til fremstilling af et lægemiddel | |
DE602007008179D1 (de) | Führungsdrahtstruktur mit medizinischem Führungsdraht |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |